SynBiotic (SCALE: SBX)

Last close As at 11/10/2024

EUR5.90

−0.20 (−3.28%)

Market capitalisation

EUR28m

SynBiotic is an investment vehicle that pursues an EU-focused buy-and-build approach. The core business of the platform company is the R&D of new cannabinoid and terpene-based solutions for the health issues of pain, sleep and anxiety.

Latest Insights

View More

Consumer | Outlook

SynBiotic — Platform primed for growth

Consumer | Outlook

SynBiotic — Building the platform

Consumer | Update

SynBiotic — Management update – on track

Consumer | Update

SynBiotic — Further acquisitions

Sector

Consumer

Equity Analyst

Russell Pointon

Russell Pointon

Director of Content, Consumer and Media

Key Management

  • Daniel Kruse

    CEO

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 0.3 (23.4) 47.5
Relative (5.1) (26.7) 17.7
52 week high/low €13.9/€2.9

Financials

SynBiotic has built up a leading platform company that spans the hemp and cannabis industry to cover the full value chain, from cultivation through to sales. Management buys and builds ventures that create and market hemp, cannabis and cannabinoid products for both medical and recreational use, while continually seeking investments in exciting new verticals. Recreational cannabis use has recently been partially legalised in Germany, while the same legislative changes have benefited the medicinal market. Having built its platform prior to these changes, SynBiotic is seeing its investments bear fruit and we believe it is well-positioned for any further relaxation in cannabis legalisation in Germany.

Research

Update

Consumer

SynBiotic — Further acquisitions

QuickView

Consumer

SynBiotic — Building a cannabis platform

Initiation

Consumer

SynBiotic — Working together

Thematics

thematic

Consumer

ConsumerWatch – The times they are a-changin’

thematic

Consumer

ConsumerWatch – Give me a reason to love you

thematic

Consumer

ConsumerWatch – At least someone loves me

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free